Our results showed that the administration of IL‐1R and IL‐6R antagonists failed to prevent body weight loss, improve lung integrity and oedema resolution, and reduce the inflammatory response in bleomycin‐challenged mice at day 7. The gene discussed is IL1R1; the disease is edema.